Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC

NCT07026474 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

214

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Head and Neck Squamous Cell Carcinoma

Interventions

OTHER: radiotherapy
DRUG: Cisplatin
DRUG: Pembrolizumab
DRUG: cisplatin + 5-fluorouracil (5FU)
DRUG: Alternative medications: carboplatin + 5-fluorouracil (5FU)
DRUG: Alternative medications: carboplatin
DRUG: Pembrolizumab

Sponsor

Universität des Saarlandes